US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.